Clinical pharmacology of paclitaxel in relation of patient age: CALGB 9762

Li Liu, MD

University of Pennsylvania Cancer
Ultima Vez Modificado: 13 de mayo del 2001

Share article


English

Presenter: S.M. Lichtman
Affiliation: CALGB, Chicago, IL

Background:

    The taxanes are one of the most important new classes of anticancer agents to emerge in the last decade. Paclitaxel, one of the two taxanes, has been widely used in patients with various malignancies, especially in the elderly population. However, its pharmacokinetics and pharmacodynamics among elderly population have not been established.

Materials and Methods:

  • A total of 148 patients, age 55 years or older, with various non
  • hematologic malignancies were included in this prospective study
  • Total body Clearance (TBC) and toxicity of paclitaxel were evaluated
  • None of the patients received paclitaxel previously
  • There were 3 patient cohorts: 55
  • 64 years, 65
  • 74 years, and 75 years and older

Results:

  • Age is a significant factor in total body clearance, AUC, and decline in WBC nadir
  • The decline in absolute neutrophil count was not statistically significantly associated with age
  • Age is significantly associated with grade 3 ANC toxicity

Authors' Conclusions

  • There is decreased paclitaxel clearance with age
  • There is increased myelosuppression with age

Clinical/Scientific Implications:

  • There is significant interpatient variability in paclitaxel clearance and age related changes account for only of modest proportion
  • Clinical trials evaluating the effects of aging on pharmacology of anticancer in cooperative trials are feasible

ASCO Abstract 265

Saturday | Sunday | Monday | Tuesday

OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen

English
News
ASCO: Fewer Side Effects With Weekly Paclitaxel in Breast CA

Jun 4, 2013 - For women with breast cancer, low-dose weekly paclitaxel is as effective as the standard-dose regimen given every two weeks, with fewer side effects; and axillary radiotherapy may be better than axillary lymph node dissection in the case of positive sentinel lymph node biopsy, according to two studies presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información